



Biological therapies for rheumatoid arthritis: non-TNF inhibitors

JOHN H.Y. MOI MB BS

RUSSELL R.C. BUCHANAN MB BS, MD, FRACP

Following on from an earlier article by these authors on tumour necrosis factor (TNF) inhibitors for rheumatoid arthritis, this second article focuses on the non-TNF inhibitors. These highly effective biological therapies have radically changed how rheumatoid arthritis is managed, helping patients achieve not only disease control but also long-term remission.

MedicineToday 2012; 13(1): 59-63

Therapy for rheumatoid arthritis (RA) is directed at interrupting the inflammatory process, which, left unchecked, causes irreversible joint damage, deformity and long-term functional impairment. The earlier therapy is initiated, the better the long-term outcomes in patients with RA. Methotrexate is the main disease-modifying antirheumatic drug (DMARD) used for the treatment of RA and remains the gold standard of first-line therapy. However, an emerging class of biological DMARDs is now available for patients who fail to respond to methotrexate monotherapy and/or combination therapy with other traditional DMARDs. Treatment with these new biological DMARDs is designed to specifically target the immune response underlying the development and progression of RA.

Part one of this two-part series on biological therapies for RA introduced this class of agents and focused on the tumour necrosis factor (TNF) inhibitors (see *Medicine Today*, October 2011, pages 87-92). This second instalment discusses the non-TNF inhibitors.

The non-TNF inhibitors are a class of biological DMARDs that inhibit proinflammatory cytokines other than TNF that are also considered to also play a central pathogenic role in the development of rheumatoid synovitis and RA.^{1,2} The main non-TNF inhibitors used to treat patients with RA are tocilizumab, abatacept, rituximab and anakinra (Table).^{1,2} There are also a number of emerging biological

Dr Moi is a Rheumatology Registrar and Associate Professor Buchanan is Director of the Rheumatology Unit at Austin Health, Heidelberg, Vic.

TABLE. NON-TNF INHIBITORS AVAILABLE ON THE PBS^{1,2}

Non-TNF inhibitor biological DMARDs	Route of administration	Mechanism of action	Use in pregnancy: drug category
Tocilizumab	Monthly IV infusion of 8 mg/kg, (up to a maximum of 800 mg)	Monoclonal antibody to IL-6 receptor	C
Abatacept	Monthly IV infusion dosed according to bodyweight (<60 kg = 500 mg; 60 to 100 kg = 750 mg; >100 kg: 1000 mg), following an initial loading dose given at zero, two and four weeks	CTLA-4–1gG1 fusion protein, an inhibitor of T-cell costimulation	C
Rituximab	Two 1000 mg IV infusions given two weeks apart. Repeat dosing is not usually given for at least six months following the first infusion	Chimeric monoclonal antibody binding to CD-20 on premature B-cells	C
Anakinra	SC injection of 100 mg, daily	Soluble IL-1 receptor antagonist	B1

ABBREVIATIONS: TNF = tumour necrosis factor; CTLA-4 = cytotoxic T-lymphocyte antigen 4; CD-20 = cluster of differentiation 20; DMARD = disease-modifying antirheumatic drug; IgG1 = immunoglobulin G subclass 1; IL-1 = interleukin 1; IL-6 = interleukin 6; IV = intravenous; SC = subcutaneous.

agents currently in the pipeline and undergoing clinical trials, for example, ocrelizumab, ofatumumab, epratuzumab and veltuzumab.

TOCILIZUMAB

Tocilizumab is a recombinant humanised monoclonal antibody that binds both soluble and membrane-bound interleukin-6 (IL-6) receptors.³ IL-6 is a pro-inflammatory cytokine found in the synovium of patients with active RA.² It acts as a major inducer of the hepatic acute phase proteins, such as C-reactive protein, and serum levels of IL-6 correlate with markers of disease activity in RA. IL-6 promotes osteoclast maturation, which is responsible for bone erosion and radiographic abnormalities in RA.^{2,3} The cytokine also plays a role in inducing B-cell differentiation and in T-cell² and macrophage activation.⁴

In trials of tocilizumab in patients with RA, clinical improvement were observed as early as four weeks after the initiation of therapy, with improvement becoming most pronounced by week 12.³ Furthermore, data from a one-year open-label

trial of 158 patients confirm the superiority of tocilizumab over traditional DMARD therapy in slowing the development of radiographic changes.⁴ As noted in part one of this series, it is desirable to coprescribe biological DMARDs with methotrexate, and combination therapy with tocilizumab and methotrexate has been shown to increase the efficacy of the drug.⁶

Indication

Tocilizumab is clinically indicated for the treatment of moderate-to-severe RA. It can be prescribed under the Pharmaceutical Benefits Scheme (PBS) by rheumatologists (or clinical immunologists with experience managing RA) for the treatment of adult patients with severe active RA who fail to achieve adequate disease remission following either:

- six months of treatment (including at least three months of continuous treatment) with at least two traditional DMARDs, one of which must be methotrexate unless contraindicated
- an unsuccessful trial of therapy with a TNF inhibitor.

Dosing and administration

Tocilizumab is administered as a monthly intravenous infusion. The recommended dose is 8 mg/kg administered every four weeks. The maximum recommended dose of tocilizumab is 800 mg per infusion.

Side effects

Upper respiratory tract infection was the most commonly documented adverse event associated with tocilizumab in clinical trials.⁶ Headache, skin eruptions, stomatitis and fever were less common.⁵ Pathology abnormalities encountered during clinical trials included elevated lipid profiles, neutropenia and abnormal levels of liver enzymes.² Significant elevations in total cholesterol, triglyceride and HDL levels were also observed, the significance of which is yet to be determined.

Laboratory monitoring of lipid parameters at four- to eight-weekly intervals for the first six months of treatment and at three-monthly intervals thereafter is advisable. Furthermore, the institution of cholesterol-lowering agents is sometimes warranted.

A dose-dependent, reversible neutropenia can occur at any time during treatment. Treatment interruption may be considered following discussion with the treating specialist if the patient's neutrophil count falls to less than 1×10^9 U/L.

Transient liver function abnormalities (e.g. elevated levels of transaminase and bilirubin) may also occur in a dose-dependent manner, predominantly involving aspartate aminotransferase more than alanine aminotransferase. Treatment interruption may be appropriate in cases in which hepatic transaminase levels exceed three to five times the upper limit of normal. In most patients, liver function test abnormalities normalise within eight weeks after the last infusion.^{4,6}

Cases of bowel perforation complicating diverticulitis have also been reported in association with tocilizumab therapy. Patients with a history of intestinal ulceration, diverticulitis and concomitant corticosteroid use should be closely monitored for symptoms suggestive of potential gastrointestinal toxicity during treatment with tocilizumab.⁷

ABATACEPT

Abatacept is a soluble fusion protein comprised of the human cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunoglobulin and the Fc portion of human IgG1.²

RA has traditionally been regarded as a T-cell-mediated disease. In patients with RA, autoantigen-specific T-cells are activated and expand in joints and/or lymph nodes in response to stimulation by antigen-presenting cells (APCs) that convey arthritis-related peptides.^{4,8} For T-cell activation to occur in these patients, two equally important processes or signals are required:

- recognition of a specific antigen by the T-cell – this 'first signal' involves T-cell receptor interaction with the human leukocyte antigen class II molecule on the APC

- a costimulatory signal – this 'second signal' involves binding of an APC costimulatory ligand to a T-cell receptor, forming a receptor-ligand pair.⁹

Abatacept acts as a selective inhibitor of this costimulatory or 'second signal' required for T-cell activation. This is achieved by abatacept binding to CD-80 and CD-86 and thus inhibiting T-cell response.

Clinical responses to abatacept have been observed as early as day 15 following treatment initiation. Continued clinical improvements were recorded until trial conclusion at 12 months.¹⁰ This suggests a slightly slower mode of action than the cytokine inhibitors. A statistically significant reduction in radiographical progression compared with placebo after one year of treatment has also been noted.¹⁰

Indication

Abatacept is indicated in combination with methotrexate for the treatment of moderate-to-severe RA in adult patients who have experienced an insufficient response or intolerance to therapy with traditional DMARDs. The same PBS requirements outlined for tocilizumab also apply to abatacept.

Dosing and administration

Abatacept is dosed according to bodyweight (e.g. less than 60 kg = 500 mg; 60 to 100 kg = 750 mg; greater than 100 kg = 1000 mg). Abatacept is administered as a 30 minute infusion and should be given at two and four weeks following the initial infusion, and then at four-weekly intervals thereafter. A weekly 125 mg subcutaneous preparation has been shown to be equally effective as the intravenous form, but it is not yet available on the PBS.

Side effects

The overall incidence of adverse events in clinical trials was similar between the

abatacept- and placebo-treated groups.¹⁰ The most commonly reported adverse events included headache, nasopharyngitis, dizziness and nausea. Hypersensitivity reactions (hypotension, dyspnoea, urticaria or wheezing) occurred rarely. Serious infections were noted in up to 3.9% of patients receiving combination therapy with abatacept plus methotrexate versus 2.3% of patients treated with placebo plus methotrexate.¹⁰

It is recommended that GPs therefore remain vigilant for signs of infections that are seen more commonly in patients receiving abatacept (in particular pneumonia [abatacept 0.4 to 0.9% *v.* placebo 0 to 0.5%]).¹⁰ Other infections to be aware of in patients being treated with abatacept are cellulitis, urinary tract infections and diverticulitis.

Opportunistic infections and malignant diseases are thought to occur at similar frequencies between patients treated with abatacept and placebo.^{4,10} Routine laboratory monitoring for patients receiving abatacept follow the same recommendations outlined for TNF inhibitor therapy: three-monthly monitoring of full blood examination, urea and electrolyte levels, liver function tests and inflammatory markers.

RITUXIMAB

Rituximab is a genetically-engineered chimeric human/mouse monoclonal antibody, directed against the CD20 antigen expressed on the surface of mature and premature B-cells.²

B-cells have been shown to play an integral role in the disease pathogenesis of RA. Their pathogenic role is thought to be mediated through either (auto)antibody and/or proinflammatory cytokine production, or possibly antigen presentation.⁴

Rituximab is an effective chemotherapeutic agent in the treatment of CD20 positive B-cell non-Hodgkin's lymphoma and was initially approved for this indication.¹¹ Recognition of rituximab's

therapeutic potential in RA is a more recent development.¹² Treatment with rituximab causes transient depletion of CD20-positive B-cells. This occurs without affecting stem cells or plasma cells, thereby allowing new B-cells to develop after six months.¹¹⁻¹³

In clinical trials for RA, B-cell depletion occurred rapidly, as assessed by CD19 positive cell counts. Response to rituximab was apparent within eight weeks of treatment, with changes in radiographical endpoints showing a trend towards slower progression of joint damage in rituximab-treated patients.^{4,14}

Indication

Rituximab is considered a second-line biological DMARD and is indicated in combination with methotrexate for the treatment of adult patients with severe RA. Patients are required to demonstrate an inadequate treatment response to at least one TNF inhibitor to qualify for rituximab therapy on the PBS.

Dosing and administration

Rituximab is administered intravenously as two doses of 1000 mg, given two weeks apart. Rituximab can be administered concomitantly with the dose of methotrexate tolerated by the patient. The timing of retreatment is largely determined by disease activity, but rituximab therapy is generally not repeated until 24 weeks after the first infusion.⁴

Side effects

Acute infusion reactions (e.g. pruritus, rash, urticaria/angioedema, fever, chills, rigors, bronchospasm, with or without alterations in blood pressure) are the most commonly reported adverse events associated with the use of rituximab for RA. Reactions occur most often during (or within 24 hours of) the first infusion, and tend to abate with subsequent doses. The rate of serious infections necessitating intravenous antibiotics per

100 patient-years was 3.7 in the placebo group versus 5.2 for rituximab-treated patients.¹⁴ The most common infections reported in both groups were upper respiratory tract infections, nasopharyngitis, urinary tract infections, bronchitis and sinusitis.

GPs should therefore remain vigilant for signs of infections affecting these systems and implement appropriate antimicrobial therapy as needed. There was no suggestion of increased incidence of malignant diseases or opportunistic infections associated with rituximab in clinical trials.⁴ Routine laboratory monitoring for patients receiving rituximab follows the same recommendations outlined for TNF inhibitor therapy and as stated previously for abatacept.

Development of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain, has been associated with the use of rituximab. Patients who develop new or worsening neurological symptoms or signs suggestive of PML require a complete neurological assessment, including a physical examination, an MRI scan and CSF testing for John Cunningham viral DNA. Rituximab must be permanently discontinued if a diagnosis of PML is confirmed.¹²

ANAKINRA

Anakinra is a recombinant IL-1 receptor antagonist. IL-1 is a central proinflammatory cytokine implicated in synovial inflammation in RA.

Anakinra has been shown to improve clinical, laboratory and radiographical measures of disease activity in RA^{2,15} – albeit less effectively than other biological DMARDs.^{5,7} The benefits of receiving IL-1 treatment with anakinra in patients with RA have been observed as early as 24 weeks in clinical trials.¹⁵

Indication

As a result of unsuccessful negotiations concerning price, anakinra was removed

from the PBS as a biological DMARD for treatment of severe active RA in 2010. Anakinra remains available on private prescription for the treatment of active adult RA in patients who have had an inadequate response to one or more DMARD.¹⁶ The agent is recognised as an effective (off-label) therapeutic option for treating adult onset Still's disease, systemic onset juvenile onset Still's disease and cryopyrin-associated periodic fever syndromes, including familial Mediterranean fever (which affects mainly children).⁷

Dosing and administration

Anakinra is generally well tolerated, but has a short half-life, necessitating daily administration of 100 mg via subcutaneous injection.² Treatment should be given in combination with methotrexate.

Side effects

Mild, transient injection-site reactions were identified as the most commonly reported adverse event in clinical trials. Other adverse events, including neutropenia, neoplasia and infection, were rarely observed and resulted in withdrawal of the patient from the study.^{15,16}

WHICH BIOLOGICAL DMARD IS THE MOST EFFECTIVE?

As more biological DMARDs become available, an important question in clinical practice asks which biological DMARD is the most effective agent for treating RA in patients who fail to respond to traditional DMARD therapy?

To date, no head-to-head comparisons have been performed to help answer this question. Apart from the apparent lower efficacy of anakinra, all other biological DMARDs are reported to be equally effective in the treatment of RA.⁵ The final decision on which biological DMARD to use is

ultimately influenced by the available evidence and also by factors including, but not limited to, individual patient comorbidities, patient preference and the requirements of the PBS.

EMERGING THERAPIES

Although a cure for RA remains elusive, the search for new medications and better treatment strategies continues to be the focus of ongoing research. A large and promising group of emerging therapies involves targeting molecules intrinsic to the intracellular signal transduction pathways involved in the pathogenesis of RA. Therapeutic targets identified within this class of biological agents include the janus-kinase/signal transducer and activator of transcription (JAK/STAT) pathways, spleen tyrosine kinase (Syk) and the mitogen-activated protein kinases (MAPKs).¹⁷

Therapeutic targets

JAK/STAT

JAK binds the cytoplasmic region of transmembrane-cytokine receptors, resulting in STAT activation, which acts as a transcription factor. There are four JAK subtypes, of which JAK3 plays an essential role in signal transduction for IL-2, IL-4, IL-9, IL-15 and IL-21. These interleukin pathways are integral to lymphocyte activation, function and proliferation.

In phase II clinical trials, a new oral JAK3 inhibitor tofacitinib has been reported to effect clinical improvement as early as 12 weeks in measurements of pain, disability and quality of life. Phase III studies have been reported in Poster format showing similar efficacy.^{17,18}

Syk

Syk is an important mediator of immunoreceptor signalling in macrophages, neutrophils, mast cells, synovial fibroblasts and B-cells. The net downstream effect of Syk activation includes increased IL-6 and matrix metalloproteinase

production. A recently published phase II clinical trial confirmed the positive impact of Syk inhibition on reducing disease activity, and supported the Syk pathway as a potential new drug target for the treatment of RA.¹⁹

MAPKs

MAPKs are intracellular enzymes that transmit signals to the nucleus resulting in gene transcription. They have been found in the synovial lining and endothelium of vessels within RA synovium. MAPKs have been implicated in regulating TNF, IL-1 and IL-6 signalling, and animal studies had demonstrated their efficacy in reducing joint swelling and damage.^{4,6}

New generation monoclonal antibodies

New generation monoclonal antibodies are also on the horizon for RA treatment. Following the success of rituximab, four new humanised B-cell-depleting therapies are under current evaluation: ocrelizumab, ofatumumab, epratuzumab, and veltuzumab. Research is also under way on developing monoclonal antibodies against novel targets, such as IL-17 (secukinumab) and the haemopoietic regulators granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (mavrilimumab).¹⁷

CONCLUSION

Methotrexate remains the drug of choice for the treatment of patients with active RA. There is evidence it is equally efficacious as the biological agents in the treatment of early RA. In patients whose disease is inadequately controlled either with methotrexate treatment or with a combination of other non-biological DMARDs, there is an array of highly effective agents that are now available to treat the disease. The availability of these emerging biological agents – some of which are

available in tablet form – has radically changed the approach towards RA management.

The prescription of these new therapies remains in the domain of the specialist rheumatologist (or immunologist with experience in managing RA). However, GPs play a vital role in both providing early patient referral for specialist evaluation and in partnering with specialists monitoring patients for the development of treatment- and disease-related complications. The expectation of treatment is now no longer to simply palliate patient symptoms, but to render patients with early RA into long-term remission. **MT**

REFERENCES

A list of references is available on request to the editorial office.

This article is for general information purposes only, and the full product information should be consulted before prescribing any of the mentioned medications.

COMPETING INTERESTS: None.



Who wants your opinion? We do.

Did you find a particular article in this issue helpful in your practice? Do you have something to say about an article we have published or some of the opinions expressed? Write and tell us, and we will consider your letter for publication. We are more likely to print short letters (no longer than 250 words), so please be succinct.

Write to:

Medicine Today, PO Box 1473,
Neutral Bay, NSW 2089,
or email:
editorial@medicinetoday.com.au

Biological therapies for rheumatoid arthritis: non-TNF inhibitors

JOHN H.Y. MOI MB BS

RUSSELL R.C. BUCHANAN MB BS, MD, FRACP

REFERENCES

1. Singh JA, Christensen R, Wells GA, et al. Cochrane Database Syst Rev 2009; (4): CD007848.
2. Feely MG, Erickson A, O'Dell JR. Therapeutic options for rheumatoid arthritis. *Expert Opin Pharmacother* 2009; 10: 2095-2106.
3. An MM, Zou Z, Shen H, Zhang JD, Cao YB, Jiang YY. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Eur J Clin Pharmacol* 2010; 66: 49-59.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. *Lancet* 2007; 370: 1861-1874.
5. Nam JL, Winthrop K, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010; 69: 976-986.
6. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum* 2006; 54: 2817-2829.
7. Updated recommendations for the use of biological agents for the treatment of rheumatic diseases: Australian Rheumatology Association; 2011. Available online at: www.rheumatology.org.au/downloads/FINAL-BiologicalRecommendations060111.pdf (accessed January 2012).
8. Choy EH, Panayl GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med* 2001; 344: 907-916.
9. Delves PJ, Roitt IM. The immune system: second of two parts. *N Engl J Med* 2000; 343: 108-117.
10. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. *Ann Intern Med* 2006; 144: 865-876.
11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum* 2006; 54: 1390-1400.
12. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. *Blood* 2009; 113: 4834-4840.
13. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. *Semin Arthritis Rheum* 2010; 39: 327-346.
14. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum* 2006; 54: 2793-2806.
15. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 1998; 41: 2196-2204.
16. Anakinra (Kineret) to be deleted from the PBS. NPS RADAR; 2010: Available online at: www.nps.org.au/health_professionals/publications/nps_radar/2010/august_2010/brief_item_anakinra (accessed January 2011).
17. Buch MH, Emery P. New therapies in the management of RA. *Curr Opin Rheumatol* 2011; 23: 245-251.
18. Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis Care Res (Hoboken)*. 2011; 63: 1150-1158.
19. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavay DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Engl J Med*. 2010; 363: 1303-1312.